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Objective: To determine some of the neuropsychiatric manifestations of systemic lupus 
  erythematosus (SLE) by applying multimodal neurophysiological and psychometric studies.
Patients and methods: Twenty-six SLE patients were evaluated for neurological and 
  psychiatric disorders and compared with 26 healthy controls matched for age, sex, education, 
and social class. The severity of SLE disease was assessed. Each subject was subjected to the 
following examinations: laboratory, neurophysiology, magnetic resonance imaging of the brain, 
transcranial duplex, Modified Mini-mental State Examination, Cognitive Assessment Scale 
Inventory, Hamilton Depression Scale, and Hamilton Anxiety Scale.
Results: The mean age of subjects was 25.9 ± 8.9 years. The most prevalent neurological 
manifestations were (in order of frequency) anxiety in 17 cases (65.4%), depression in 15 cases 
(57.7%), headache in 10 cases (38.5%), peripheral neuropathy in 7 cases (26.9%), seizures in 
6 cases (23.1%), psychosis in 5 cases (19.2%), dementia in 4 cases (15.4%), radiculopathy 
in 4 cases (15.4%), myositis in 3 cases (11.5%), and stroke in 2 cases (7.7%). There was 
a significant affection in amplitude of the ulnar nerve, cognitive function impairment, and 
  electroencephalography changes. There was a significant increased mean velocity and decreased 
Pulsatility Index of the most studied intracranial vessels in the patients.
Conclusion: The use of multimodal neurophysiological, transcranial duplex, and psychometric 
scales increases the sensitivity for detecting nervous system involvement.
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Introduction
Systemic lupus erythematosus (SLE) is a multisystem disease with a spectrum of 
  clinical manifestations and a variable course characterized by exacerbation and 
remission.1 In the course of SLE, a variety of neuropsychiatric disturbances is reported, 
with prevalence rates ranging from 17% to 75%.2 The challenge in patients with SLE 
is to determine whether neuropsychiatric affection is functional due to a psychogenic 
basis or an organic abnormality such as dysfunction of the central or peripheral nervous 
system.1 Furthermore, if the cause is organic, are those symptoms or findings due to 
lupus itself (either active or inactive) or to other causes? A previous report3 on the 
prevalence of neuropsychiatric affection from most to least prevalent is as follows: 
cognitive dysfunction, headache, mood disorder, cerebrovascular changes within 
intracranial vessels, seizures, polyneuropathy, anxiety, and psychosis.
The use of multimodal neuropsychiatric evaluations is essential for diagnosis of 
early affection. Electroencephalography (EEG) may be helpful to confirm changes 
or diffuse encephalopathy.1 Electromyography (EMG) and nerve conduction studies International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Dovepress
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(NCS) provide useful data in the clinical assessment of 
peripheral complications of SLE.4 Transcranial duplex (TCD) 
confirms that subclinical cerebrovascular changes affect 
intracranial vessels in SLE.4 The aim of the present study 
was to characterize the potential neurological involvement 
of unselected SLE patients and index of disease activity.
Patients and methods
Twenty-six SLE patients (24 females and 2 males) with 
ages ranging from 10 years to 40 years were selected at 
the   outpatient clinic wards of Assiut and Al-Azhar (Assiut) 
  University Hospitals, Egypt. All patients met the diagnostic 
criteria of SLE.5 Rheumatologic evaluation was   completed 
using the Systemic Lupus Erythematosus Disease   Activity 
Index (SLEDAI).6 Exclusion criteria included: i) age 
below 10 years or more than 40 years; ii) pre-existing 
clinical   cardiovascular or cerebrovascular events (angina, 
myocardial infarction, transient ischemic attack, or stroke); 
iii) other   systemic   diseases (such as renal, liver, or endocrinal 
  diseases) or   taking drugs known to have central nervous 
system effects; or iv) cancer discovered in the previous 
5 years. Medications at the time of the study included non-
steroidal anti-inflammatory drugs, prednisone (10–20 mg/d) 
in all cases and disease-modifying anti-rheumatic drugs 
(hydroxychloroquine,   azathioprine, methotrexate, and 
cyclophosphamide).
SLEDAI measures the current status of SLE disease 
  activity according to clinical and laboratory   manifestations. 
SLE   disease activity is defined as the reversible manifestations 
of the underlying inflammatory process.6 SLEDAI consists 
of 24 weighted attributes, which are grouped into 9 
domains, called organ systems (weighting in parenthesis): 
central   nervous system (8), vascular (8), renal (4), 
  musculoskeletal (4), serosal (2), dermal (2),   immunologic (2), 
  constitutional (1), and hematologic (1). SLEDAI is a   reliable 
and valid instrument for measuring the clinical state of SLE 
patients.6,7
Twenty-six healthy individuals matched for age, sex, 
number of education years, and socioeconomic status8 were 
selected as a control group from relatives of patients. These 
control groups were examined and fully investigated.
The Regional Ethical Committee of Assiut University 
Hospitals and Al-Azhar (Assiut) approved the study. All sub-
jects gave their written informed consent for participation.
Methods
All subjects (patients and control) were subjected to full 
medical, neurological, and rheumatological examination 
and socioeconomic status assessment.8 Multimodal 
neurophysiological and psychometric tests were applied for 
all subjects. Venous blood was obtained from all subjects 
by puncturing an antecubital vein at 8 a.m. after overnight 
fasting. A complete blood count was performed using 
automated cell counter, and blood urea and serum creatinine 
were measured by the spectrophometeric method. Nor-
mal ranges were as follows: blood urea 30–50 mg/dL and 
serum creatinine ,1.5 mg/dL.9 Liver function tests were 
  performed by a spectrophotometeric method using Stat Fax 
(Awareness Technology, Dubai, United Arab Emirates). 
Normal ranges were as follows: aspartate aminotransferase 
0–35 U/L and alanine aminotranferease 0–35 U/L.10   Fasting 
blood glucose was measured by spectrophotometeric 
method, complete urinalysis was performed by microscopic 
examination, and 24-hour collection of urine protein was 
by spectrophotometeric method. Disease activity indexes 
such as erythrocyte sedimentation rate using the western 
green tubes method were considered normal when less than 
10 mm/hour.11 Antinuclear (ANA) and anti-double-stranded 
DNA (anti-dsDNA) were measured using enzyme-linked 
immunosorbent assay method and determined in controls to 
exclude the presence of autoimmune diseases.
Imaging studies
All subjects underwent magnetic resonance imaging of the 
brain and transcranial duplex (TCD). TCD was   carried out 
using Nicolet Bravo model 460 SNF0000001544  (Neuro-
care, Madison, WI) with a 2 mHz probe, which provided a 
direct and noninvasive assessment of subclinical atheroscle-
rosis. TCD examinations were performed at the Department 
of Neurology and   Psychiatry, Clinical Neurophysiology Unit, 
Assiut   University Hospital. The right anterior cerebral artery 
(ACA) was assessed via transtemporal window. The depth 
of insonation was between 60 mm and 90 mm with subject 
head in a neutral position. The right middle cerebral artery 
(MCA) was assessed via a transtemporal window. The depth 
of insonation was between 30 mm and 60 mm with subject 
head in a neutral position. Right posterior cerebral artery 
(PCA) was assessed via transtemporal window. The depth 
of insonation was between 60 mm and 80 mm with subject 
head in a neutral position. Right vertebral artery (VA) was 
assessed via suboccipital window. The depth of insonation 
was between 60 mm and 90 mm with subject head in a 
neutral position. Right basilar artery (BA) was assessed via 
suboccipital window. The depth of insonation was between 
80 mm and 120 mm with subject head in a neutral position. 
Systolic mean velocity (MV) and Pulsatility Index (PI) International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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were recorded as PI equal to the peak velocity minus the 
end-diastolic velocity divided by the MV .12 The PI normal 
range is 0.5–1.1.13
Neurophysiologic studies
Conventional 20-minute EEG recordings were obtained using 
the 8-channel Nicolet Bravo model 460 SNF0000001544. 
The electrodes were placed on the scalp according to the 
International 10–20 System of Electrode Placement using 
bipolar and referential montages. Hyperventilation was used 
as a provocative test. Seizures were divided into epilepsy 
(chronically recurrent seizures occurring in a stereotypic 
pattern corresponding to anatomically focal spikes on EEG) 
and isolated seizures (usually corresponding to generalized 
slowing on EEG).
Motor nerve conduction velocity (MCV) studies were 
performed on the right ulnar, median, and common peroneal 
nerves. MCV , distal latency (DL), and amplitude of compound 
muscle action potential (CMAP) were measured with standard 
surface stimulating and recording techniques. The latency 
was measured from the stimulus onset to the beginning of the 
initial deflection of the CMAP. The MCV can be calculated 
by stimulating at two different points along the nerve and 
measuring the latency for each response. F-wave (for median, 
ulnar, and common peroneal nerves) was measured by   putting 
the recording electrodes on the distal muscle innervated by 
the testing nerve, employing the belly-tendon method. F-wave 
latency was measured from the start of the stimulus to the 
onset of initial deflection of the F-wave with the shortest 
latency. The latency of the F-wave after distal stimulation is 
usually in the range of 23–33   milliseconds for median and 
ulnar nerves in normal individuals and of 50–60 milliseconds 
for the peroneal nerves.
An H-reflex study was measured by placing the recording 
electrodes on the gastrocnemius muscle and stimulating the 
posterior tibial nerve at the popliteal fossa. The latency was 
measured from the start of stimulation to the onset of the 
initial deflection of the H-reflex. The latency of the H-reflex 
is usually in the range of 25–35 milliseconds in normal 
individuals.
Psychometric
The Cognitive Abilities Screening Instruments (CASI) 
  consists of 25 test items and provides quantitative assessment 
of attention, concentration, orientation, memories for post-
knowledge and present input, language abilities, drawing 
and writing abilities, list-generating ability, abstract thinking, 
and judgment.14 The CASI is more comprehensive than most 
screening tests of cognitive abilities and can be used to screen 
for early cognitive impairment and dementia. We   considered the 
cutoff of CASI as that according to Ross et al,15 which is #67 
points for dementia. The Mini-mental State Examination 
(MMSE) is a widely used scale for screening for dementia.16 
Most of the subjects of the present study were illiterate. The two 
points testing reading and writing were excluded, and the full 
score was calculated as 28 instead of 30 points. The cutoff point 
of dementia was 21 instead of 23 points.17 In the present study, 
dementia was diagnosed if the clinical presentation fulfilled 
criteria of dementia as well as when the subject scored #21 on 
the MMSE and #67 on the CASI.18 The Hamilton Depression 
Scale is a widely used and reliable scale and not specific for 
elderly people.19 The cutoff point of depression in this scale is 
$17, according to Michele and Bolino.20 Numerous authors 
have since investigated the dimensionality of the scale and 
demonstrated that it is multidimensional.19 The Hamilton 
Anxiety Scale lists 14 types of symptom. The total score ranges 
from 0 to 56. A total score of 18 or more means anxiety.21
Statistical analysis
The computer software package SPSS® for Windows 
(Version 16) (IBM, Chicago, IL, USA) was used for the data 
analysis. Continuous variables such as age were expressed 
as mean ± standard deviation, whereas categorical variables 
such as gender were presented as frequencies (%). The 
Pearson Chi-square test and independent-sample t-test did 
not assume equal variances were used. A series of Pearson 
correlation coefficients was used to examine SLEDAI and 
different variables. Significance level was set at P # 0.05.
Results
Details of demographic data, systemic examination, and 
laboratory data are illustrated in Tables 1 and 2. There were 
Table 1 Demographic data of patients and control group 
Item Control  
N = 26
Cases  
N = 26
P value
Age (mean ± SD) 25.9 ± 8.9 24.9 ± 7.6 0.65
Sex
  Male (n%) 2 (7.7%) 2 (7.7%) 0.383
  Female (n%) 24 (92.3%) 24 (92.3%)
Duration of illness  
(mean and range/years)
4.85  
(1–15 years)
number of education  
years (mean ± SD)
3.7 ± 0.55 3.8 ± 0.02 0.93
Socioeconomic status  
(mean ± SD)
12.6 ± 2 12.05 ± 1.6 0.33
Notes: Unless otherwise indicated, data are expressed as mean ± standard deviation 
(SD) when normally distributed.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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nonsignificant differences between cases and controls 
with regard to age, sex, number of education years, and 
socioeconomic status. The most prevalent neuropsychiatric 
manifestation was anxiety in 17 cases (65.4%),   depression 
in 15 cases (57.7%), headache in 10 cases (38.5%), 
  peripheral   neuropathy in 7 cases (26.9%), isolated seizures 
in 6 cases (23.1%), psychosis in 5 cases (19.2%), dementia in 
4 cases (15.4%), radiculopathy in 4 cases (15.4%), myositis 
in 3 cases (11.5%), and stroke in 2 cases (7.7%).
Electrophysiological and EEG data are summarized in 
Tables 3 and 4. There was a significant difference between 
amplitude of motor NCS of the ulnar nerve of SLE patients 
and the control group, which means an increased incidence 
of ulnar axonal neuropathy in SLE patients. Abnormal EEG 
findings such as high-voltage slow waves and spike slow 
waves and sharp waves were observed in 19 cases (73.1%) of 
SLE but in only 6 cases (23.1%) in the control group.
Table 5 illustrates the significant decline in most studied 
cognitive function tests among the SLE group compared with 
the control group. In addition, there were higher results in 
the Hamilton Depression Scale and Hamilton Anxiety Scale. 
Table 3 Motor conduction studies of peripheral nerves in cases 
compared with the control groups 
Item Control  
N = 26
Cases  
N = 26
P value
Distal latency (ms)
 •  Median   3.4 ± 0.245   3.3 ± 0.48 nS
 •  Ulnar    2.32 ± 0.3   2.56 ± 0.55 nS
 •  common peroneal   3.75 ± 0.55   3.98 ± 0.62 nS
Amplitude (MV)
 •  Median  12.32 ± 2.96   9.86 ± 5.6 nS
 •  Ulnar 11.08 ± 1.94   7.56 ± 2.91 0.000
 •  common peroneal   4.41 ± 1.33   4.01 ± 4.37 nS
Motor nerve  
conduction (ms)
 •  Median  65.25 ± 6.38 62.58 ± 10.19 nS
 •  Ulnar  64.61 ± 7.44 62.36 ± 8.4 nS
 •  common peroneal 51.72 ± 4.29 51.02 ± 7.7 nS
F-wave latency (ms)
 •  Median  24.54 ± 1.16 25.08 ± 4.38 nS
 •  Ulnar  24.17 ± 1.4 24.07 ± 2.13 nS
 •  common peroneal 27.52 ± 2.84 28.27 ± 3.36 nS
H-reflex of tibial (ms) 27.36 ± 4.15 28.38 ± 1.03 nS
Notes: Unless otherwise indicated, data are expressed as mean ± standard deviation 
when normally distributed.
Abbreviations: MV, mean velocity; NS, nonsignificant.
Table 4 electroencephalograph (eeG) in cases compared with 
the control group 
Item Control  
N = 26
Cases  
N = 26
Chi-square   
P value
normal eeG 20 (76.9%) 7 (26.9%) 0.000
Abnormal eeG
 •  Focal sharp or slow wave
 •  Focal slowing 
 •  Diffuse slowing
6 (23.1%) 
2 (7.7%) 
4 (15.4%) 
0
19 (73.1%) 
8 (30.8%) 
5 (19.2%) 
5 (19.2%)
0.003
Side of focal changes
 •  Generalized 
 •    On one hemisphere  
with secondary  
generalization
6 (23.1%) 
0
13 (50%) 
5 (19.2%)
0.005
 •  changes appeared
° Without provocation 
  ° With provocation
2 (7.7%) 
4 (15.4%)
9 (34.6%) 
9 (34.6%)
0.003
 •  repetition
° ,5 
  ° .5–10 
  ° .10
6 (23.1%) 
0 
0
7 (26.9%) 
5 (19.2%) 
7 (26.9%)
0.000
Notes: Data are expressed as number and percentage.
Table 2 clinical, laboratory, radiological, and neurological data 
of the patients 
Clinical data Data recorded (N = 26)
Systemic manifestations (fever, fatigue, 
malaise, anorexia, and weight loss)
22 (88%)
cutaneous
  Malar rash 24 (92.3%)
  Photosensitivity 25 (96.2%)
Arthralgia 26 (100%)
Arthritis 23 (88.5%)
renal 17 (65.4%)
Gastrointestinal findings 7 (26.9%)
Cardiovascular system findings 9 (34.6%)
Pulmonary findings 3 (11.5%)
Daily Activity Index 17.76 ± 6.35
neuropsychiatric manifestation
 •  Anxiety 17 (65.4%)
 •  Depression 15 (57.7%)
 •  headache 10 (38.5%)
 •  Peripheral neuropathy 7 (26.9%)
 •  Isolated seizures 6 (23.1%)
 •  radiculopathy 5 (19.2%)
 •  Psychosis 4 (15.4%)
 •  Dementia 4 (15.4%)
 •  Myositis 3 (11.5%)
 •  Stroke 2 (7.7%)
AnA (+ve) 24 (92.3%)
Anti-dsDnA antibody (+ve) 21 (80.8%)
Significant proteinuria (.0.5 g/d or 3+)  
or cellular casts
20 (76.9%)
hematologic disorder
 •  Anemia 26 (100%)
 •  Thrombocytopenia 3 (11.5%)
 •  Leucopenia 9 (34.6%)
eSr 20 (76.9%)
Abnormal MrI of the brain 0 (0%)
Notes: Data are expressed as number (percent). 
Abbreviations: AnA, antinuclear antibody; anti-dsDnA, anti-double-stranded DnA; 
eSr, erythrocyte sedimentation rate; MrI, magnetic resonance imaging.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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There was a significant increased MV and decreased PI of 
most studied intracranial vessels in both patient groups 
compared with the control group. There was a significant 
increased MV of ACA and VA and nonsignificant decreased 
PI of most studied intracranial vessels in the patient group 
compared with the control group (Table 6).
To examine the relationship between SLEDAI cognitive 
function subscales, laboratory findings, and TCD studies of 
all patient groups (Table 7), a series of Pearson correlation 
coefficients was calculated. There were significant negative 
correlations between SLEDAI and short-term memory, CASI 
drawing and fluency, and MCA and PCA PI.
Discussion
Neurophysiological and psychometric studies may help 
to characterize the potential meaning of subclinical 
neurological involvement. Moreover, they may favor more 
accurate diagnosis and may provide clinicopathological 
information regarding its nature.23 In this study, neuro-
physiological studies helped in the diagnosis of neurological 
abnormalities in clinically silent neurological or psychiatric 
disorders in patients with SLE. The most common type 
of neuropsychiatric abnormalities recorded in this study 
was anxiety, followed by depression, headache, peripheral 
neuropathy, seizures, psychosis, dementia, radiculopathy, 
myositis, and stroke.
Among NCS, the amplitude of MCV of the ulnar nerve is 
significantly reduced among SLE patients compared with the 
control group. These changes indicated predominant axonal 
neuropathy rather than demyelinating neuropathy among 
SLE patients. That can be explained by vascular changes 
rather than other pathological causes of neuropathy, although 
the pattern of MCV does not permit such a differentiation 
without a nerve biopsy. This was in agreement with results 
obtained by Khedr et al in 2001.24 They noted a significant 
reduction in amplitude of motor NCS of ulnar, median, 
and common peroneal nerves among SLE patients compared 
with the control group. Also, our results were in agreement 
with Hanly,25 who reported that sensorimotor neuropathy had 
been found in up to 28% of SLE patients and frequently occur 
independently of other disease characteristics.8
Abnormal EEG findings were observed in 19 cases 
(73.1%) but in only 6 cases (23.1%) in the control group. 
That result was in agreement with Khedr et al in 200124 in 
Table  7  Pearson  correlation  between  systemic  lupus  erythe-
matosus disease activity index and cognitive function subscales, 
laboratory findings, TCD studies
R value P value 
cASI Short-term memory  -0.434 0.030a
cASI drawing -0.479 0.013a
CASI fluency -0.429 0.029a
Laboratory AnA   0.522 0.006b
TcD McA PI -0.414 0.035a
PcA PI -0.449 0.021a
Notes:  aCorrelation  is  significant  at  the  0.05  level  (2-tailed);  bcorrelation  is 
significant at the 0.01 level (2-tailed); Only significant data are expressed.
Abbreviations: AnA,  antinuclear  antibody;  cASI,  cognitive Abilities  Screening 
Instruments;  McA,  middle  cerebral  artery;  PcA,  posterior  cerebral  artery;   
PI, Pulsatility Index; TcD, transcranial duplex.
Table 5 cognitive function, depression, and anxiety in patients 
compared with control
Item Control  
N = 26
SLE  
N = 26
P value 
MMSe score 28.15 ± 1.9 25.81 ± 4.74 0.025
cASI
  Long-term memory   9.5 ± 1.0   8.04 ± 2.12 0.002
  Short-term memory   9.9 ± 1.8   7.37 ± 2.94 0.000
  Attention   8.1 ± 0.74   7.23 ± 0.86 0.000
    Mental manipulation/
concentration
  8.3 ± 2.1   6.00 ± 3.08 0.002
  Orientation   16.2 ± 3.3 15.88 ± 2.76 nS
  Drawing   8.1 ± 2.8   7.96 ± 2.94 nS
    Abstract thinking and 
judgment
  8.8 ± 2.9   7.31 ± 2.81 nS
  Fluency 4-legged animals   9.7 ± 0.6   8.19 ± 2.83 0.009
  Language   7.8 ± 2.0   7.47 ± 1.74 nS
  cASI total score   86.6 ± 9.6 74.49 ± 17.33 0.003
hamilton Depression Scale   6.0 ± 0.6 16.31 ± 8.45 0.000
hamilton Anxiety Scale     7.5 ± 8.3 
(1.607)
20.00 ± 9.37 0.000
Notes: Unless otherwise indicated, data are expressed as mean ± standard deviation 
when normally distributed.
Abbreviations:  cASI,  cognitive  Abilities  Screening  Instruments;  MMSe, 
Modified  Mini-mental  State  Examination;  NS,  nonsignificant;  SLE,  systemic  lupus 
erythematosus.
Table 6 Intracranial vessels affection in patients and control
Item  Control  
N = 26
SLE  
N = 26
PI
McA    MV (cm/s) 
PI
53.04 ± 9.24 58.94 ± 11.85 nS
  0.66 ± 0.1   0.71 ± 0.18 nS
AcA    MV (cm/s) 
PI
41.15 ± 24.92 52.39 ± 11.04 0.0141
  0.67 ± 0.13 0.64 ± 0.14 nS
PcA       MV (cm/s) 
PI
48.81 ± 11.26 50.45 ± 11.06 nS
  0.61 ± 0.15 0.63 ± 0.12 nS
VA       MV (cm/s) 
PI
34.54 ± 17.61 45.47 ± 6.67 0.006
  0.58 ± 0.08 0.58 ± 0.13 nS
BA         MV (cm/s) 
PI
42.88 ± 5.05 44.64 ± 21.10 nS
  0.63 ± 0.09 0.61 ± 0.11 nS
Notes: Data are expressed as mean ± standard deviation.
Abbreviations: AcA, anterior cerebral artery; BA, basilar artery; McA, middle 
cerebral artery; MV, mean velocity (cm/s); NS, nonsignificant (the mean difference is 
significant at the 0.05 level [equal variances not assumed]); PCA, posterior cerebral 
artery; PI, Pulsatility Index; SLe, systemic lupus erythematosus; VA, vertebral artery.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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which abnormal EEG findings were observed in 73% of 
cases. In the present study, the most common abnormality 
was diffuse slow activity, which is generally considered a 
sign of organic brain disease and is the most common EEG 
abnormality recorded for SLE.24 This is matched with pre-
vious studies that reported EEG abnormalities among SLE 
patients.24,27 In addition, there are significant differences 
between lupus patients and controls with regard to most 
studied EEG findings.
Among the many neurological involvements of SLE, 
cognitive impairment is becoming increasingly recognized.24 
Cognitive function is significant impairment in patients 
with SLE in comparison with controls in the present study, 
mainly in short- and long-term memories, attention, mental 
manipulation/concentration, fluency, and total scores of 
MMSE and CASI scales. There is no specific or unique 
pattern of cognitive impairment in SLE, and many individual 
patients have subclinical deficits. For example, a review 
of 14 cross-sectional studies of cognitive function in SLE 
revealed subclinical cognitive impairment in 11%–54% of 
patients.25 Fisk et al28 reported that two patterns of memory 
dysfunction had been identified in SLE patients. Impaired 
remote memory appears to be associated with a history of 
past central nervous system (CNS) involvement (suggesting 
the presence of a residual neurological deficit), whereas 
impaired immediate memory and concentration implies 
increased disease activity that may represent transient and 
diffuse CNS effects.28 These deficits are not specific to one 
brain region or one neuropsychological process, and may 
reflect both multifocal and diffuse brain diseases. Monastero 
et al29 proposed that a frontal temporoparietal dysfunction 
might account for the cognitive deficits found in patients with 
SLE. Positron emission tomography (PET)/single photon 
emission computed tomography (SPECT) studies30 revealed 
a hypoperfusion in the frontal, temporal, and parietal lobes 
mainly in SLE patients.
However, we cannot be completely sure that these 
cognitive changes are due to the lupus itself or possibly 
to a manifestation of chronic disease not specific to SLE 
or neurospsychiatric SLE. A recent paper by Hanly et al31 
demonstrated that there was essentially no difference between 
SLE, rheumatoid arthritis, and multiple sclerosis patients in 
cognitive function.
There were significantly higher scores for Hamilton 
Depression Scale and Hamilton Anxiety Scale in patients 
with SLE than in the control group, which matches the study 
by Nery et al.32 Thirty-five cases out of 71 (49.2%) presented 
with major depression, and 37 cases (52.1%) presented with 
anxiety disorders. Several factors might explain these high 
prevalence rates and include the stress of having a chronic 
disease and the high doses of corticosteroids commonly 
used in its treatment.33 On the other hand, there is intriguing 
evidence suggesting that some patients with SLE may have 
organic forms of depression caused by autoimmune lesions 
in the CNS. For instance, the antiribosomal P antibody is 
highly associated with both lupus psychosis and severe 
depression.33 Furthermore, neuropsychiatric disorders due 
to SLE activity, such as seizures, strokes, aseptic meningitis, 
delirium, and psychosis, may also be associated with con-
comitant   depressive symptoms.33 Nery et al32 hypothesized 
that the high prevalence of some anxiety disorders could be 
linked to feelings of embarrassment experienced in public by 
some SLE patients due to the skin and facial disfigurements 
that can result from the disease or treatment. Although a 
magnetic resonance imaging scan of the brain in all cases 
was normal, there was early detection of cerebrovascular 
affection using TCD findings in this study. The middle 
cerebral artery stem is relatively easy to study. Ultrasound 
has a sensitivity and specificity of 90%–99% for finding a 
stenosis or an occlusion. For the more difficult to image 
intracranial segment of the vertebral arteries and the BA, 
ultrasound has a sensitivity of 70%–80% and a specificity 
of 90%–99%.34
There are significant increased mean velocities and 
decreased PI of most studied intracranial vessels. In previous 
studies, most pathologic conditions affecting the large 
  intracranial arteries result in narrowing, constriction,   stenosis, 
or occlusion of the vessel, which results in increased mean 
flow velocity and decreased PI.13,35 These results were 
matched with a study35 of 167 patients with SLE evaluated 
by the TCD technique. Results could not be obtained for 
14 patients due to technical difficulties. In the remaining 
153 patients, results of 138 TCD techniques were normal, 
and 15 patients (9%) had one or more abnormalities.36
Our results are consistent with the recent article by 
  Gasparovic et al,37 which demonstrated increased   cerebral 
blood flow and cerebral blood volume that could be 
  consistent with increased mean velocities and decreased PI. 
This basically demonstrated that neurospsychiatric SLE is 
often associated with hyperperfusion and that the areas of 
decreased perfusion observed by PET or SPECT may actually 
be normal perfusion in certain situations and misinterpreted 
as areas of reduced perfusion. Our results are consistent with 
this interpretation. Increased mean velocities and decreased 
PI could be due to cerebrovasodilation and increased cerebral 
blood flow.37International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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In this study, abnormalities on TCD (PI) were significantly 
correlated with clinical disease activity as measured 
by   SLEDAI in the form of MCA (P = 0.035 and PCA 
(P = 0.021). These results agree with those of the study by 
Kron et al.36 These abnormal findings in TCD in this study 
can be attributed to the development of vascular changes 
in SLE, which lead to narrowing and stenosis of cerebral 
blood vessels.
SLEDAI is a reliable and valid instrument for measuring 
the clinical state in patients with SLE.37 In this study, 
  significant negative Pearson correlations were found between 
SLEDAI, MCA PI, PCA PI, and some cognitive function 
tests such as short-term memory, drawing, and   fluency. 
In   addition, significant positive correlation was found 
between SLEDAI and ANA laboratory findings. The study of 
SLEDAI and its correlations is important. With most human 
attributes, SLE disease activity cannot be measured directly. 
What is being measured is the observed phenomenon that 
indicates the existence of this attribute. Assessment of SLE 
disease activity is challenging due to the multisystem nature 
of this disease with its diverse range of possible manifesta-
tions, as any part of the body can be affected. Furthermore, 
involvement of a system could lead to various manifestations, 
adding to its complexity.38,39 Moreover, we can explain these 
significant correlations as an increase in severity of the dis-
ease with more deterioration in cognitive function.
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